本研究正在測試一種使用質子治療（PT）的較短程前列腺癌治療方法，質子治療非常精準，與傳統放射治療相比可能引起較少副作用。然而，其費用昂貴且許多患者難以獲得。為使其更可負擔及更易獲得，本研究正在測試2次分次的立體定向身體質子治療（SBPT）能否與標準5次治療同樣安全有效。
適應症：Prostate Cancer Patients Treated by Radiotherapy
收案條件
納入條件
- Men aged \< 18 years with histologically confirmed low- or intermediate-risk prostate cancer per NCCN guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status \<2
- Ability to undergo magnetic resonance imaging (MRI) simulation scans without absolute contraindications, such as cardiac implantable electronic devices
- Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
排除條件
- History of inflammatory bowel disease or other cancers (except prostate cancer)
- Prior pelvic radiotherapy, chemotherapy, radical prostatectomy, cryosurgery, or focal therapy (e.g. high-intensity focused ultrasound \[HIFU\]) for prostate cancer
- History of bladder neck or urethral stricture
- Transurethral resection of the prostate (TURP) \< 8 weeks prior to SBPT
- Prostate volume \> 100cc on MRI
- Unilateral or bilateral hip replacements
- Nodal or distant metastases, as indicated by computed tomography (CT), MRI, or prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans
- Previous androgen deprivation therapy (ADT) lasting more than 6 months
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。